Evaluation of diagnostic discordance in rare paediatric disorders between two large-scale genomic sequencing studies
Background Genome-wide sequencing is increasingly being used in research and clinical practice for diagnosing rare disorders, but there remain substantial differences in diagnostic yields between studies. Identifying important factors that could maximise diagnosis is challenging due to differences between cohorts and lack of appropriate truth sets. Methods We identified patients that were independently enrolled into both the Deciphering Developmental Disorders Study (DDD) and subsequently the 100,000 Genomes Project (100kGP) and then compared candidate diagnostic variants prioritised by the two different studies. Results We identified 1,598 patients that were independently enrolled into both DDD and 100kGP. Comparing results returned, we found that 32% of patients received a genetic diagnosis in one or both studies. However, despite similar diagnostic yields within each study, we found that only ~ 70% of diagnoses made in one study were concordant with the other. Numerous differences throughout the testing pathway contributed to the overall diagnostic discrepancy, including: gene panel (DDG2P versus PanelApp) content and inheritance modes; number of family members recruited; patient and parent phenotyping; variant detection, filtering and prioritisation rules; and clinical variant classification. Differences were likely exaggerated by an enrichment of complex phenotypes in families enrolled sequentially into multiple projects, and incomplete clinical assessment at the time of analysis. Conclusions Despite many similarities, differences in the testing pathway between DDD and 100kGP resulted in substantial differences in the diagnoses identified. Each step in the testing pathway contributes to achieving the best opportunity to identify a molecular diagnosis, including the family members tested and their affected status, the phenotypic description provided, the gene panels selected, the timing of the test and the bioinformatics parameters used. Notably, alternative bioinformatics pipelines and reanalysis strategies had a larger effect on diagnostic yield than the additional coverage provided by genome versus exome sequencing. Ensuring high-quality phenotyping, performing regular reanalysis using an up-to-date knowledge-base, and tracking progress in variant classification and diagnostic assessment should be priorities for enhancing genomic medicine services.
Authors
- V. Kartik Chundru (ORCID: https://orcid.org/0000-0002-6348-5565)
- Hassan Shakeel
- Susan Walker (ORCID: https://orcid.org/0000-0002-5016-6426)
- Patrick H. Campbell
- Petr Danecek (ORCID: https://orcid.org/0000-0002-4159-1666)
- Ruth Y. Eberhardt (ORCID: https://orcid.org/0000-0001-6152-1369)
- Nour M. Elkhateeb (ORCID: https://orcid.org/0000-0002-3076-3178)
- Eamonn G. Sheridan (ORCID: https://orcid.org/0000-0002-7237-6280)
- Dalia Kasperavičiūtė (ORCID: https://orcid.org/0009-0008-4672-6305)
- Helen V. Firth (ORCID: https://orcid.org/0000-0002-6410-0882)
- Caroline Fiona Wright (ORCID: https://orcid.org/0000-0003-2958-5076)
- Sarah Lindsay (ORCID: https://orcid.org/0000-0002-0965-3070)
- Erwan Delage (ORCID: https://orcid.org/0000-0002-7653-5111)
- Matthew E. Hurles (ORCID: https://orcid.org/0000-0002-2333-7015)
- Hilary C. Martin (ORCID: https://orcid.org/0000-0002-4454-9084)
- Rachel J. Hobson (ORCID: https://orcid.org/0000-0003-1997-9557)
- Cassandra Smith (ORCID: https://orcid.org/0000-0002-2517-2824)
- Sana Amanat (ORCID: https://orcid.org/0000-0002-1211-6890)
- K. Savage
- Ana Lisa Taylor Tavares
- Tom Marchant
Institutions
- Guy's Hospital (GB)
- University of Exeter (GB)
- St James's University Hospital (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Wellcome Sanger Institute (GB)
- Genomics England (GB)
- King's College Hospital (GB)
Publication Details
- Journal
- Genome Medicine
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1186/s13073-026-01836-2
- Primary Topic
- Genomics and Rare Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00